Group 1 - Company repurchased 93,500 shares at HKD 5.23 per share on December 19, totaling approximately HKD 490,000, with a cumulative repurchase of about 3.44 million shares in December, amounting to over HKD 17.4 million [1] - The repurchase actions reflect the company's confidence in its future development and aim to strengthen market confidence [1] - The founder and chairman of the company, Gong Rujing, was appointed as a member of the advisory committee of the Digital Medicine Research Institute at City University of Hong Kong, indicating recognition from the industry and academia for the company's innovations in AI healthcare [1] Group 2 - The company has made significant strides in international cooperation, being selected as a member of the newly established Health Sustainable Development Working Committee of the Shanghai Cooperation Organization's multi-functional economic and trade platform [1] - The co-founder and CEO, Xu Jiming, was elected as the first council member of the committee, highlighting the company's professional capabilities and authoritative recognition in the international digital health cooperation field [1] - The company's international strategy has expanded its business and client network to six global regions, establishing a mature localized cooperation ecosystem through collaboration with local governments, medical institutions, and research institutes [2]
医渡科技12月以来11次回购，多重国际认可彰显发展信心